Pharmaceutical Approaches to Presbyopia Management

Overview
Emerging pharmaceutical options for the treatment of individuals with presbyopia are poised to enter the eye care landscape. This novel approach represents a completely new paradigm for eye care providers to consider when discussing the array of options available with patients. This independent educational activity is supported by an unrestricted educational grant from Allergan.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the underlying mechanisms of presbyopic changes.
- Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting (PC) options.
- Differentiate among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action (MOA).
- Explain how PC drops are likely to affect categories of patients based on individual characteristics.
- Compare the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.
Accreditation
Evolve Medical Education LLC (Evolve) is an approved COPE administrator This course is COPE approved for 1.5 hours of CE Credit for Optometrists Course: 69921-AS Activity #: 120429
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers: Internet Explorer 11 for Windows Edge (recent versions; Chromium-based) for Windows Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
FACULTYMilton H. Hom, OD, FAAO Program Chair Private practice Azusa, California Mile Brujic, OD, FAAO Partner, Premier Vision Group Bowling Green, Ohio Ian Benjamin Gaddie, OD, FAAO Owner and Director Gaddie Eye Centers Louisville, Kentucky Selina McGee, OD, FAAO Founder Precision Vision of Edmond Edmond, Oklahoma Adjunct Assistant Professor Northeastern State University College of Optometry Tahlequah, Oklahoma DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests: Mile Brujic, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of speaking, writing, participating in an advisory capacity, research or meeting support from: ABB Optical, Akorn, Alcon Laboratories, Allergan, Art Optical, Bausch + Lomb Health, Blephex, Contamac, CooperVision, CSEye, Euclid, Eyevance, Horizon Therapeutics, Johnson & Johnson Vision Care, Luneau, Novartis, Oculus, Optovue, Sight Sciences, Sun Pharma, Tangible Science, TelScreen, TruForm Optics, Valley Contax, Visionary Optics, VMax Vision, Walman Optical, Weave, Carl Zeiss Meditec, and Zea Vision. Ian Benjamin Gaddie, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerie, Allergan, Bausch & Lomb, Ivantis, Novarris and Sight Sciences. Grant/Research Support: Aerie. Stock/Shareholder: Tarsus, and Leo Lens. Milton M. Hom, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Grant/Research Support: Allergan, Eyenovia, and Novartis. Speaker’s Bureau: Allergan. Selina R. McGee, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Cynosure, Dompe, Eyevance, Horizon, Lumenis, Novartis, Optovue, Versant, Vertical. Speaker’s Bureau: Allergan, Lumenis, and Optovue. The Evolve Medical Education staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 12/05/2020

Title

Share on ReachMD